Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 7;23(1):45.
doi: 10.1186/s12959-025-00716-w.

Enoxaparin dosing for venous thromboembolism prophylaxis in hospitalized underweight adult patients: a retrospective cohort study

Salam Ibrahim Abou Safrah  1 , Mohamed Omar Saad  2 , May Alasmar  1 , Fatima Ashfaq Butt  1 , Somaya Khaled Koraysh  3
Affiliations

Enoxaparin dosing for venous thromboembolism prophylaxis in hospitalized underweight adult patients: a retrospective cohort study

Salam Ibrahim Abou Safrah et al. Thromb J. .

Abstract

Background: Enoxaparin is commonly used for venous thromboembolism (VTE) prophylaxis in adult hospitalized patients. Although anti-Xa levels are inversely related to body weight, limited studies evaluated clinical outcomes of dose reduction in the underweight population.

Objective: To compare the incidence of bleeding and VTE in underweight patients receiving reduced doses of enoxaparin (< 40 mg daily) versus the standard dose (40 mg daily) for VTE prophylaxis.

Methods: This was a multicentre retrospective cohort study at Hamad Medical Corporation in Qatar. We included hospitalized patients with a total body weight ≤ 57 kg or body mass index (BMI) ≤ 18.5 kg/m2 who received prophylactic enoxaparin for at least 48 h. The outcomes were bleeding, VTE, and composite unfavourable outcome (bleeding or VTE). Inverse-probability-of-treatment weighting (IPTW) was used to adjust for confounding.

Results: We identified 1,130 eligible patients, of whom 124 patients (11%) received the reduced dose, and 1,006 patients (89%) received the standard dose. Bleeding occurred in one patient (0.8%) of the reduced dose group compared to 15 patients (1.5%) in the standard dose group (p > 0.99), VTE occurred in two patients (1.6%) in the reduced dose group compared to four patients (0.4%) in the standard dose group (p = 0.13). In the IPTW analysis, there was no significant difference in overall bleeding (odds ratio (OR) 1.4, 95% CI 0.18-10.75, p = 0.74), VTE (OR 0.3, 95% CI 0.05-1.81, p = 0.19), or the composite unfavourable outcome (OR 0.74, 95% CI 0.2-2.75, p = 0.66).

Conclusion: There is no significant difference in the incidence of bleeding or VTE between the reduced dose and the standard dose of enoxaparin for VTE prophylaxis in underweight adult patients. Due to the low event rates in both groups, larger studies are required to delineate any differences between the two dosing strategies.

Keywords: Body mass index; Deep vein thrombosis; Dose; Enoxaparin; Prophylaxis; Venous thromboembolism; Weight.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Hamad Medical Corporation Medical Research Centre approved this research (MRC- 01- 22–477). Medical Research Centre waived the informed consent due to the retrospective nature of the study. After data extraction and validation, we replaced patient identifiers with unique study codes to protect patients’ privacy. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of patient selection, showing the total cohort screened, reasons for exclusion, and the final study population. BMI: Body mass index; CrCl: creatinine clearance. *atrial fibrillation (3 patients), acute coronary syndrome (5 patients), left ventricular thrombus (one patient), aortic thrombosis (one patient)
Fig. 2
Fig. 2
Incidence of overall bleeding and venous thromboembolism by enoxaparin dose
Fig. 3
Fig. 3
Cumulative incidence function of overall bleeding (A) and venous thromboembolism (B)
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e195S-e226S. - PMC - PubMed
    1. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8:2450–7. - PubMed
    1. Wolberg AS, Rosendaal FR, Weitz JI, Jaffer IH, Agnelli G, Baglin T, et al. Venous thrombosis Nat Rev Dis Primer. 2015;1:15006. - PubMed
    1. Enoxaparin. Lexi-Drugs. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc.; 2022. Available from: http://online.lexi.com/lco/action/home. Cited 2022 Jul 24.
    1. Levin A, Ben-Artzi M, Beckerman P, Haber G, Varon D, Ben-Yehuda A, et al. Factors Associated with Bleeding in Elderly Hospitalized Patients Treated with Enoxaparin Sodium: A Prospective, Open-Label. Observational Study Drugs Aging. 2009;26:77–85. - PubMed

LinkOut - more resources